This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Colfax (CFX) to Gain From Demand & Buyouts Amid Cost Woes
by Zacks Equity Research
Colfax (CFX) to gain from robust demand, product innovation, cost actions and synergies from buyouts. Inflation in raw material costs and supply-chain issues are likely to hurt.
Colfax (CFX) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Colfax (CFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CFX vs. NDSN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CFX vs. NDSN: Which Stock Is the Better Value Option?
Colfax (CFX) Tops Q2 Earnings & Sales Estimates, Hikes View
by Zacks Equity Research
Colfax's (CFX) Q2 earnings increase y/y on the back of strengthening end markets and margin improvement. For 2021, the company raises earnings and free cash flow projections.
Colfax (CFX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Colfax (CFX) delivered earnings and revenue surprises of 5.66% and 7.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Colfax (CFX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Colfax (CFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
A. O. Smith (AOS) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
A. O. Smith's (AOS) Q2 earnings might have benefited from its solid position in the replacement market and focus on product developments. Low commercial water heater demand might have been a woe.
Fortune Brands (FBHS) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Fortune Brands' (FBHS) Q2 earnings are likely to have benefited from strength across its businesses and acquired assets. High operating costs and expenses might have been a spoilsport.
Ingersoll Rand (IR) to Post Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Ingersoll Rand's (IR) Q2 earnings might have benefited from its solid aftermarket businesses, acquired assets and product portfolio. Risks related to international presence might have been a woe.
Colfax (CFX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Colfax (CFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CFX or FLS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CFX vs. FLS: Which Stock Is the Better Value Option?
Colfax (CFX) Stock Up 19.3% YTD: What's Driving the Rally?
by Zacks Equity Research
Colfax (CFX) is poised to benefit from strong demand for its products, solid product portfolio, acquired assets and healthy cash flows.
Colfax (CFX) Beats Q1 Earnings Estimates, Increases View
by Zacks Equity Research
Colfax's (CFX) Q1 earnings surpass estimates and improve year over year on sales and margin improvement. For 2021, it raises bottom-line projections.
Will Illinois Tool (ITW) Keep Its Earnings Streak Alive in Q1?
by Zacks Equity Research
Illinois Tool (ITW) Q1 results to reflect gains from solid product offerings, diverse businesses, improving manufacturing activities and enterprise strategy. Pandemic woes are likely to have hurt.
Why Colfax (CFX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Colfax (CFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in the Offing for 3M (MMM) This Earnings Season?
by Zacks Equity Research
End-market challenges, high restructuring expenses and forex woes are likely to have affected 3M's (MMM) Q1 performance. Solid demand for respirators and acquired assets might have aided.
General Electric (GE) to Post Q1 Earnings: Beat in the Cards?
by Zacks Equity Research
General Electric's (GE) Q1 earnings are likely to have gained from strong digital business and solid demand for pandemic-related products. Weak commercial aftermarket business might be a drag.
Colfax (CFX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Colfax (CFX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allegion (ALLE) to Post Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Allegion (ALLE) Q1 earnings are expected to have gained from solid demand for electronic security products and strong residential businesses despite the coronavirus outbreak-led issues.
Colfax (CFX) to Redeem $700M Worth Senior Notes Due 2024 & 2026
by Zacks Equity Research
Colfax (CFX) to redeem $700 million worth of senior notes that are due to expire in 2024 and 2026. The move will help the company to lower its debt balance.
Why Is Colfax (CFX) Up 10.6% Since Last Earnings Report?
by Zacks Equity Research
Colfax (CFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Colfax (CFX) Commences Public Offering of 14M Common Shares
by Zacks Equity Research
Colfax (CFX) offers 14 million common shares to the public in an underwritten offer. The funds raised will be used for funding general corporate purposes and working capital needs.
Will Cintas (CTAS) Keep Its Earnings Streak Alive in Q3?
by Zacks Equity Research
Cintas' (CTAS) Q3 earnings results to reflect the impacts of one less working day and the pandemic-related woes. The healthy demand in hygiene and healthcare markets is likely to have been appealing.
Colfax (CFX) Plans to Split Businesses Into Separate Companies
by Zacks Equity Research
Colfax's (CFX) plan of dividing its fabrication technology and medical technology businesses into two separate companies will likely unlock significant values for each of its businesses.